Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators

[1]  J. Hugosson,et al.  Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. , 2022, The New England journal of medicine.

[2]  G. Troncone,et al.  Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives , 2022, Cancers.

[3]  R. Velotta,et al.  A Combinatorial Neural Network Analysis Reveals a Synergistic Behaviour of Multiparametric Magnetic Resonance and Prostate Health Index in the Identification of Clinically Significant Prostate Cancer. , 2022, Clinical genitourinary cancer.

[4]  G. Kristiansen,et al.  A randomized trial of risk‐adapted screening for prostate cancer in young men—Results of the first screening round of the PROBASE trial , 2022, International journal of cancer.

[5]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[6]  Dr. Bashar Matti,et al.  Age-Adjusted Reference Values for Prostate Specific Antigen - A Systematic Review and Meta-Analysis. , 2021, Clinical genitourinary cancer.

[7]  F. Walter,et al.  Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients , 2021, BMC Medicine.

[8]  H. Grönberg,et al.  Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. , 2021, The Lancet. Oncology.

[9]  H. Grönberg,et al.  MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. , 2021, The New England journal of medicine.

[10]  J. Nevalainen,et al.  Number of screening rounds attended and incidence of high‐risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) , 2020, Cancer.

[11]  T. H. van der Kwast,et al.  A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. , 2019, European urology.

[12]  Eric A. Miller,et al.  Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial , 2018, The Prostate.

[13]  Martin Eklund,et al.  The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. , 2018, European urology.

[14]  J. Sterne,et al.  Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial , 2018, JAMA.

[15]  J. Gohagan,et al.  Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years , 2017, Cancer.

[16]  J. Hébert,et al.  Prostate Specific Antigen‐Growth Curve Model to Predict High‐Risk Prostate Cancer , 2017, The Prostate.

[17]  T. Tammela,et al.  Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study. , 2016, European urology.

[18]  Martin Eklund,et al.  Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. , 2015, The Lancet. Oncology.

[19]  R. Grobholz,et al.  A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening. , 2015, European urology.

[20]  John W. Scott,et al.  A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. , 2015, European urology.

[21]  H. Grönberg,et al.  Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. , 2015, European urology.

[22]  G. Kristiansen,et al.  Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial. , 2013, European urology.

[23]  S. Bojesen,et al.  Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality. , 2013, European urology.

[24]  M. Nichol,et al.  Changes in serum prostate‐specific antigen levels and the identification of prostate cancer in a large managed care population , 2013, BJU international.

[25]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[26]  P. Scardino,et al.  Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. , 2009, European urology.

[27]  A. Haese*,et al.  Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. , 2008, European urology.

[28]  M. Roobol,et al.  Screening for prostate cancer at low PSA range: The impact of digital rectal examination on tumor incidence and tumor characteristics , 2007, The Prostate.

[29]  J. Moul,et al.  Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. , 2007, The Journal of urology.

[30]  R. Millikan,et al.  Prostate cancer progression in the presence of undetectable or low serum prostate‐specific antigen level , 2007, Cancer.

[31]  H. Klocker,et al.  Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk , 2005, The Prostate.

[32]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[33]  J. Gohagan,et al.  Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. , 2005, Journal of the National Cancer Institute.

[34]  A. D'Amico,et al.  Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. , 2004, The Journal of urology.

[35]  B. G. Blijenberg,et al.  Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. , 2004, The Journal of urology.

[36]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[37]  A. Haese*,et al.  Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range. , 2002, The Journal of urology.

[38]  K Ito,et al.  Long term follow‐up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less , 2001, Cancer.

[39]  P C Prorok,et al.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.

[40]  J. Gohagan,et al.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. , 2000, Controlled clinical trials.

[41]  A. Miller,et al.  Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.

[42]  H. D. de Koning,et al.  Prostate cancer detection at low prostate specific antigen. , 2000, The Journal of urology.

[43]  J. Oesterling,et al.  Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. , 1996, Urology.

[44]  W. Catalona,et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.

[45]  J. Oesterling,et al.  An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx. , 1995, Urology.

[46]  W. Fair,et al.  Abbott IMx evaluated for assay of prostate-specific antigen in serum. , 1992, Clinical chemistry.

[47]  D. Siders,et al.  Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer , 1992, Cancer.

[48]  B. Mahal,et al.  Association of very low prostate‐specific antigen levels with increased cancer‐specific death in men with high‐grade prostate cancer , 2016, Cancer.

[49]  A. Gavin,et al.  Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA? , 2009, Prostate Cancer and Prostatic Diseases.